Company: UMC Utrecht
Job title: Associate Professor
Zsolt Sebestyen’s research is mainly focusing on understanding immunogenicity of tumors especially concentrating on the role of the innate immune cells. He joined the research group of Prof Juergen Kuball in 2010 in order to study the tumor recognition properties of an exciting subset of innate-like immune cells, the gamma delta T cells, and their receptors. He resolved complex dynamics of either membrane of intracellular proteins both in T cells and tumor cells that helped to understand the mode of action how these immune cells sense malignant transformation. His research interest situates between translational and basic tumor immunology: receptor engineering of immune cells uniquely allows to study tumor recognition properties of immune receptors on a controlled manner while protein and cellular dynamic studies, based on high resolution imaging give the opportunity to understand the complex dynamics of interplay between immune cell, tumor and stroma. This allowed to create pre-clinical packages to translate our basic findings into first in human clinical studies.
His findings so far do not only have a basic scientific impact but possibly will help to select patients that would benefit from immune therapies based on gamma delta T cell receptors. By developing in vitro and in vivo pre-clinical models for novel immune therapy modalities, his work helps translating basic scientific discoveries into clinical practice. Additionally, by understanding the mechanisms of tumor escape from the immune system, this work creates a unique window of opportunity to improve the safety and efficacy of immunotherapies against cancer.
Live Q&A Discussion 12:20 pm
day: Day One
Exploring Vγ9Vδ2 T Cells & Receptors 12:00 pm
• Discussing Vγ9Vδ2 T cells and receptors against solid cancer • Gamma delta T cell targeting towards solid cancers • Preclinical models to understand heterogeneity of tumors and T cell products • Mode of action of Vγ9Vδ2 TCR targeting of tumors • Highlighting the Mode of Action of Tumor Recognition by Vγ9Vδ2 TCRsRead more
day: Day One